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1. Introduction to non-medical prescribing 
1.1 Non-medical prescribing: an overview 
For many years only medical professionals (doctors and dentists) could prescribe 
medicines for human use. Initial recommendations and support for nurses to take on the 
role of prescribing were made nearly 30 years ago.1 2 By the spring of 2001 
approximately 20,000 district nurses and health visitors were qualified to prescribe 
independently from a limited list of medicines. In 1999 a further review recommended 
that prescribing authority should be extended to other groups of healthcare 
professionals.3 Although initially restricted to a limited list of medicines and conditions, 
legislation was passed in 2006 which enabled nurses to independently prescribe any 
licensed medicines for any condition within their area of competence and a number of 
controlled drugs. Independent prescribing for pharmacists was introduced in 20064 and 
in 2009 further changes in legislation enabled nurse and pharmacist independent 
prescribers to prescribe unlicensed medicines for their patients and also to mix 
medicines themselves or direct others to do so.5  
 
Forms of non-medical prescribing 
There are two distinct forms of NMP: independent prescribing and supplementary 
prescribing. 
 
Independent prescribing is done by practitioners who are responsible and 
accountable for assessing patients with undiagnosed or diagnosed conditions and for 
deciding the clinical management required, including prescribing. Independent 
prescribers can prescribe licenced or unlicenced medicines within their clinical 
competence. 
 
Supplementary prescribing is a voluntary partnership between a doctor and a 
supplementary prescriber (nurse, midwife or pharmacist NMP) to implement an 
agreed patient-specific clinical management plan (CMP) with the patient’s agreement. 
The doctor makes the initial diagnosis, then both prescribers prepare and agree the 
individualised CMP. NMPs can then prescribe within the parameters set out in the 
CMP. NMPs as supplementary prescribers remain responsible and accountable for 
their prescribing decisions. 
 
Most restrictions around controlled drugs prescribing were lifted in 20126 enabling 
nurses and pharmacists to prescribe virtually any controlled drug. Training for 
supplementary prescribing was introduced in 2003 for nurses and pharmacists7 and in 
2005 for allied health professionals (ie, physiotherapists, podiatrists/chiropodists, and 
radiographers).8 Training for independent prescribing is combined with that for 
supplementary prescribers in all higher education institutions. 
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NMP is delivered by specially trained health care professionals who have successfully 
completed the nationally recognised prescribing course and added this qualification to 
their entry in the relevant professional register. In the context of the substance misuse 
field, NMP is only provided by nurses, midwives and pharmacists. 
 
At the time of publication of the original version of this guidance, the National Treatment 
Agency for Substance Misuse (NTA) estimated that there were approximately 80 nurses 
and pharmacists working in the treatment of substance misuse who were either active 
prescribers, in training or contemplating training as non-medical prescribers (NMPs).9 A 
mapping exercise conducted by the National Substance Misuse Non-Medical 
Prescribing Forum (NSMNMPF) in the summer of 2012 located 316 NMPs in England.10  
 
1.2 Context of the guidance 
Before non-medical prescribing (NMP) was introduced, only medical prescribing was 
available to drug and alcohol misuse treatment systems. NMP was introduced to 
improve patients’ access to medicines. It makes best use of the skills of experienced 
and appropriately trained health professionals so increasing the availability, 
responsiveness and cost effectiveness of prescribing interventions. This guidance 
applies to nurse and pharmacist prescribers who practise within the context of drug and 
alcohol misuse treatment. 
 
National guidance on non-medical prescribing, patient group directions and minor 
ailment schemes in the treatment of drug misusers was published in 2007.9 Policy and 
legislative changes over the last seven years mean that this guidance needs to be 
updated. This document is intended for NMPs and all those with an interest in NMP 
including aspiring NMPs, consultants and clinical leads, service managers, NMP leads, 
colleagues from different professions (eg, doctors, psychologists, and social workers) 
and service commissioners. The document describes the factors that need to be 
considered for safely and effectively implementing NMP in substance misuse and 
addresses some of the specific challenges that the treatment of dependence presents 
for NMPs and their managers. 
 
The drug and alcohol field presents special issues because the majority of prescribing 
involves controlled drugs. It also presents special challenges in terms of complexity and 
risk issues, as people with substance misuse problems often have complex needs. 
These challenges highlight the importance of ensuring that prescribing interventions are 
based on sound evidence and are delivered by skilled and supported professionals. 
 
Since the 2012 lifting of restrictions, NMPs have been able to assess, diagnose and 
independently prescribe for the treatment of drug dependence. Previously, NMPs could 
only use supplementary prescribing to treat drug dependence – ie, they had to rely on 
doctors for a  diagnosis and to formulate a clinical management plan. Prescribing 
diamorphine, cocaine and dipipanone for the treatment of addiction continues to be 
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restricted and is only available to medical practitioners licensed by the Home Office (in 
England and Wales). 
 
The change in 2012, combined with the shift to a greater recovery focus, has provided 
NMPs with opportunities to improve treatment programmes. 
 
However, there are potential risks if providers fail to meet their obligations in terms of 
the governance and clinical support required by NMPs or if NMPs practice beyond their 
scope of practice or competence. This guidance describes the systems and processes 
that enable safe and effective delivery of NMP. 
 
1.3 Training as an NMP 
To train as an NMP specialising in substance misuse treatment, nurses must meet the 
prerequisites outlined by the Nursing and Midwifery Council (NMC). These include:  
 be a registered first-level nurse 
 have three years post-qualification experience in practice (in any area of nursing) 
 have practiced in substance misuse for at least one year immediately before 
applying for training (or for part-time staff a reasonable period to become 
competent as decided by their employer) 
 be able to provide evidence via accreditation of prior and experiential learning 
(APEL) of being able to study at degree level11 
 
Additionally the applicant must be able to show: 
 the support of their employer 
 they have been accepted onto the course 
 they have a designated medical practitioner (DMP) who has agreed to provide 
supervised practice during the course (see next section) 
 
Following graduation and a pre-registration year, pharmacists must complete two years 
of clinical practice experience. Similarly to nurses their employer should assure 
themselves that the pharmacist is competent to prescribe in their chosen area following 
training. 
 
NMP training should only to be undertaken if there is a demonstrable need for NMP and 
if there is the opportunity for the aspiring prescriber to carry out prescribing duties once 
they are qualified. This has to include access to a budget for prescribing and this must 
be agreed by their manager prior to embarking on the course.4 
 
Some courses and employers require NMP candidates to pass preparatory modules 
before starting NMP courses. This is at the discretion of the employer and the higher 
eduction institution (HEI). However, guidance for nurses sets out certain competencies 
and prerequisites: 
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 the applicant must have been assessed as competent to undertake clinical 
assessment and diagnose before applying 
 there must be a clinical need to prescribe within the role 
 they must have sufficient knowledge to apply prescribing principles to their own 
area of practice 
 they must have sufficient numeracy skills11 
 
In practice, organisations vary in what pre-qualifications they expect aspiring NMPs to 
undertake before providing funding and support for NMP training courses. For example, 
some NHS trusts require nurses to complete psychopharmacology and/or advanced 
physical health assessment modules at degree level. Other employers require potential 
candidates to complete their own (internally set and marked) numeracy or medicines 
management course. Others require candidates to pass the RCGP certificate12 in 
substance misuse. 
 
As employers become more aware of the benefits of NMP in the substance misuse field 
it is likely more nurses and pharmacists will be encouraged to train as a non-medical 
prescribers. However, nobody should be nominated to train for this role if they do not 
wish to take on the role as a prescriber.13 
 
Nurses and pharmacists training to become independent/ supplementary prescribers 
undergo a minimum of 26 days educational preparation, with an additional 12 days of 
supervised learning for pharmacists. There are different requirements for distance-
learning programmes.11 14 
 
1.4 The role of the designated medical practitioner 
In addition to the taught element, the NMP programme has 12 days in practice during 
which the student applies the knowledge learnt in the classroom to their area of 
practice. The student’s designated medical practitioner (DMP) supervises this period. 
The DMP is responsible for assessing the student’s prescribing competencies. The HEI 
that runs the prescribing course normally identifies the required outcomes and 
competencies, and guides and supports the DMP. 
 
The National Prescribing Centre (NPC) published guidance on the DMP role,13 including 
the criteria for the role (checklist A), the necessary competencies for the role (checklist 
B), and key characteristics of the role (checklist C). 
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Eligibility criteria for becoming a DMP (checklist A) 
The DMP must be a registered medical practitioner who: 
 has normally had at least three years recent clinical experience with a group of 
patients/clients in the relevant field of practice 
 is in a GP practice and is either vocationally trained or has a certificate of 
equivalent experience from the Joint Committee for Postgraduate Training in 
General Practice Certificate or is a specialist registrar, clinical assistant or a 
consultant within a NHS Trust or other NHS employer 
 has the support of the employing organisation or GP practice to act as a DMP who 
will provide supervision and support to the NMP student and opportunities to 
develop competence in prescribing practice 
 has some experience or training in teaching and/or supervising in practice 
 normally works with the trainee prescriber. If this is not possible (such as in nurse-
led services or community pharmacy), arrangements can be agreed for another 
doctor to take on the role of the DMP, provided the above criteria are met and the 
learning in practice relates to the clinical area in which the trainee prescriber will 
ultimately be working 
 
Characteristics of a competent DMP (checklist B)1 
Teaching 
knowledge 
Knowledge about teaching methods (how and when to use them) 
Teaching 
skills 
Using teaching knowledge, giving feedback, being able to observe, 
analysing, teaching the trainee to carry responsibility, encouraging 
reflection, structuring, being able to teach (professional) skills, being 
able to handle conflict, being able to communicate (including listening), 
phasing of training 
Teaching 
attitude 
Giving the trainee latitude, giving the trainee respect, being open to 
criticism, being open to criticism on his/her teaching, being interested in 
the trainee, being able to separate private life and teaching, being able 
to separate the different roles in the teaching-relationship (teacher, 
colleague), being able to cope with tension resulting from being both a 
DMP and an NMP trainer, being a role model, offering a safe 
environment, individualising training, being alert, being critical of the 
trainee and their learning process, being open to extra training to 
become a better teacher, enjoying the role of teacher, being available 
and reachable, making time for teaching, being able to see things in 
perspective, being stimulating, not profiting from the trainee, being loyal 
to the department, willing to share patients with the trainee, daring to 
give feedback, learning from the trainee 
Personality 
traits  
Enthusiasm, flexibility, self-knowledge, ability to reflect, self-insight, 
patience, integrity, enjoying their role as a DMP 
 
                                            
 
1
 Adapted from: Boendermarker PM, Schuling J, Meybroom-de Jong B, Zwierstra RP, Metz JCM (2000) What are 
the characteristics of the competent general practitioner trainer?  Family Practice, 17(6), 547-553 
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Key role and responsibilities of the DMP (checklist C) 
 establishing a learning contract with the trainee 
 planning a learning programme that will provide the opportunity for trainees to 
meet their learning objectives and gain competency in prescribing 
 facilitating learning by encouraging critical thinking and reflection 
 providing dedicated time and opportunities for trainees to observe how the DMP 
conducts a consultation/interview with patients and/or carers and the development 
of a management plan 
 allowing opportunities for trainees to carry out consultations and suggest clinical 
management and prescribing options that are then discussed with the DMP  
 helping to ensure the trainees integrate theory with practice 
 taking opportunities to allow in-depth discussion and analysis of clinical 
management using a random case analysis approach, when patient care and 
prescribing behaviour can be examined further 
 assessing and verifying that by the end of the course the trainee is competent to 
assume the prescribing role 
 
1.5 Managing external influence 
Nurses and pharmacists considering training to become NMPs need to consider the 
additional responsibilities that come with the qualification. They must be prepared to 
establish and set new boundaries of practice, balancing the sometimes conflicting 
demands of safe prescribing and patient choice and preference (eg, where a patient 
may wish to take home doses of medication before the prescriber is satisfied the person 
has achieved a stable state). In this context, external pressures can come from the 
patient, carers and other workers. 
 
Further influence on prescribing practice comes from the pharmaceutical industry and 
other providers of appliances. Anecdotal reports from NMPs indicate that the industry 
recognises that NMPs are an increasingly important target group when marketing 
established and new products. NMPs always need to be mindful of the requirement to 
carefully consider the evidence for pharmacological products and that persuasive sales 
presentations are underpinned by vested interests. 
 
Where NMPs feel they are being pressured to provide a certain intervention, they should 
remember they are responsible and accountable for their actions. Options that should be 
available to assist NMPs in making an informed and clinically-appropriate decision include 
clinical supervision with a medical or non-medical prescriber, managerial supervision, and 
discussion within peer support networks (see section 3.3).  
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1.6 Personal indemnity insurance and vicarious liability 
Following an amendment to EU Directive 2005/36/EC (Recognition of Professional 
Qualifications),15 statutorily regulated healthcare professionals will need to have an 
insurance arrangement or indemnity to cover their practices. This means that NMPs 
must have an appropriate indemnity arrangement in place when the new requirement 
becomes law some time in 2014. If they continue to practise without cover after this time 
they will be breaking the law. 
 
NMPs are professionally and legally accountable for their actions, or failure to act, and 
must be confident that they maintain the competencies necessary to perform their roles 
safely, prescribing or otherwise. However, in an employer-employee relationship an 
employer can be liable for the negligent acts or omissions of its employees, provided it 
can be shown that they took place in the course of their employment. In this case the 
employer is “vicariously liable” for the acts or omissions of an employee. 
 
The key question in any case involving vicarious liability is whether the employee was 
acting in a personal capacity or in the course of their employment. This can often be 
difficult to determine. Nor does an employer's liability end once the employee leaves the 
organisation – as the law stands, action can still be taken against an employer even 
though the person in question no longer works for them. 
 
Determining the level of appropriate cover is the responsibility of individual NMPs, as 
they are fully aware of the scope and scale of the risks associated with their practices. 
It is suggested that registered healthcare professionals refer to the guidance published 
by their professional bodies and regulators for up-to-date information on developments 
in this area and how they apply to their individual circumstances: 
 
Advice for NMPs on indemnity cover 
  Nursing Pharmacy 
Advice from 
professional 
regulator 
Nursing and Midwifery 
Council 
 
General Pharmaceutical 
Council 
Advice from 
professional body 
Royal College of Nursing 
Royal College of Midwives 
Royal Pharmaceutical Society 
 
General advice on 
indemnity cover 
NHS Employers 
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NMP in practice 
Jamie and Penny have worked in Torquay as NMPs for four years and during this 
time have established a new treatment pathway that embeds NMP within the 
treatment system. 
 
The majority of service users who need a prescribing intervention are automatically 
booked in for a non-medical assessment, which usually happens within five working 
days. The NMP completes a thorough assessment of the service user’s needs and 
develops a joint prescribing plan with them. 
 
The NMP discusses the plan with a medical practitioner and a joint decision is made 
on the appropriateness of non-medical prescribing. If NMP and medic are in 
agreement, the prescribing intervention can start without delay. 
 
In some cases the NMP considers the prescribing intervention to be too complex and 
beyond his/her competence and confidence. In these cases, a medical assessment to 
supplement the NMP assessment is arranged. 
 
This care pathway has significantly reduced the waiting times for prescribing 
interventions and has ensured that medical staff are able to prioritise working with 
those users who have more complex needs, and guarantees that the interventions are 
timely and cost effective. 
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2. Strategic development of NMP in 
substance misuse 
2.1 Information for commissioners 
Promoting independent NMP offers commissioners a powerful mechanism to enhance 
the flexibility of local care by increasing the availability and responsiveness of 
prescribing interventions so improving the experience of service users. 
 
Establishing NMP allows responsive, personalised and flexible delivery of care, and 
enhances the recovery orientation of services, in line with the recent Medications in 
Recovery report.16 NMP provides faster access to medicines, time savings and 
improved service efficiency. Incorporating NMPs alongside experienced medical 
practitioners can facilitate improved access and outcomes for a wide range of users, 
and an efficient use of resources. 
 
NMP is now well established across many clinical specialties and this includes the 
independent prescription of controlled drugs for the treatment of dependence. 
 
Commissioners need to appreciate that NMPs are independent prescribers within their 
identified area of competence, and are obliged not to practice outside that area of 
competence. It is a requirement of their professional regulators (the NMC and the 
General Pharmaceutical Council) that NMPs continue to engage in adequate ongoing 
learning, support and clinical supervision, and to maintain their competencies, including 
their competence in independent prescribing (typically integrated into the usual 
continuing professional development (CPD) processes that their employers support). 
 
The careful selection and training process, and the ongoing robust governance 
framework, enable a flexible and safe system for providing enhanced prescribing. 
However, this also means NMPs must not be expected to prescribe outside of their 
areas of competence. 
 
Many people attending drug and alcohol treatment experience unusually severe 
problems with dependence and/or complex mental and/or physical health disorders. 
Consequently, services aimed at meeting the core needs of such severely dependent 
people require suitable qualified medical practitioners to work alongside NMPs as part 
of the multidisciplinary team. Medical practitioners are trained to diagnose and manage 
patients with complex medical and psychiatric problems within substance misuse 
services, so the roles of medical and NMPs are complementary and not 
interchangeable. 
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There is currently wide variation across England in the use of independent NMP within 
substance misuse services. Commissioners will want to carefully consider the 
opportunities that now exist for promoting NMP within their prescribing services, taking 
into account the range of needs among users and how services are structured and 
delivered. Provider services will also want to consider how to develop NMP within their 
teams and in any proposed service structure when tendering for contracts. 
 
More detail about independent NMP use within the NHS and third sector can be found 
in A quick guide for commissioners, which the NPC developed to help organisations 
effectively implement NMP.17 
 
Professional regulators have published prescribing standards for their own practitioners. 
These are subject to change and up-to-date standards can be located on regulators’ 
websites. The NPC developed a generic competency framework for prescribers.18 This 
can be used as a tool to reflect on practice, and to identify CPD needs. The NPC has 
also published a guide for NHS managers to help improve their understanding of key 
issues in medicine use.19 
 
When NMP is being developed in a service for the first time, commissioners will want to 
be assured that those planning the service provide enough time for suitable current staff 
to engage in training and have access to adequate supervision and support 
arrangements. They should also consider the organisational support arrangements 
needed for qualified NMPs recruited directly to the service. Provider organisations are 
advised to have an NMP lead who will be a key resource for advice on training, support, 
clinical governance, operational frameworks and protocols, and the practical processes 
for using NMP. This role is described in more detail in section 3.2. 
 
Independent NMPs within substance misuse services offer commissioners a substantial 
new opportunity to improve quality, effectiveness, cost-effectiveness and the patient 
experience, by offering more flexible and responsive access to medicines from a wider 
range of clinicians. This innovation offers an opportunity to integrate independent NMP 
in to a practitioner’s wider therapeutic relationships and to support more flexible working 
among the wider multidisciplinary team. While NMP clearly complements, and does not 
replace, the competencies required from suitable medical practitioners, it can help to 
improve services if taken forward carefully and enthusiastically. 
 
2.2 The scope of prescribing practice for NMPs 
Prescribing usually follows a face-to-face consultation between a patient and NMP, and 
includes an assessment of the patient prior to the NMP making a prescribing decision 
with that patient. There will be instances where it is in the best interests of a patient, 
whose prescribing has already been initiated within an established system of 
care, for an NMP to apply their knowledge, skill and competence, and prescribe 
for someone they have not personally seen, in order to ensure safe continuity of 
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prescribing. Such decision to prescribe would be informed by the NMP’s knowledge of 
the nature of the comprehensive assessment(s) and of the clinical review and 
governance systems that underpin prescribing within their service. The decision to 
prescribe will follow a discussion with competent colleagues and a review of the clinical 
record. The NMP can then consider all relevant clinical information, and be in a 
position  to make an appropriate clinical judgement on prescribing in the case in 
question. 
 
In these circumstances the NMP must satisfy themselves that they: 
 have conducted an assessment of all appropriate information in order to 
prescribe safely 
 feel competent and confident to prescribe in this situation, and within the 
established system of care and clinical governance 
 
2.3 Inducting newly qualified and newly appointed NMPs into services 
Organisations using NMP are advised to have a formal governance process to 
authorise an NMP to start prescribing. 
 
No NMP is expected to, and should not, prescribe from the full range of medicines listed 
in the BNF. NMPs should only prescribe within their confidence and competence, 
usually from a list of medicines previously agreed by their employers. Depending on 
their expertise and competence, NMPs working with substance misusers may be able to 
treat common infections, and manage conditions such as wounds, withdrawal, 
constipation, alcohol-related craving, vitamin deficiency, anxiety, depression and a need 
for emergency contraception. Local decisions will need to be made, and processes 
agreed, about whether and when NMPs can independently prescribe medicines outside 
the field of substance misuse. 
 
Newly qualified NMPs may need to spend time developing confidence, starting slowly 
and gradually increasing their prescribing profile. This will also ensure the NMP is 
supported through the process of setting up and delivering safe NMP. 
 
Individual employers and NHS trusts may choose to provide additional support to newly 
qualified NMPs, including direct access to a relevant clinical expert. 
 
During this initial period, the employer and/or NMP may decide that it is appropriate for 
the newly qualified NMP to work within some constraints, such as restricting caseload 
numbers and complexity of patients, close working arrangements with a clinical expert 
(“shadowing”) and working within agreed prescribing protocols. This will identify the 
areas of expertise required of NMPs in a particular setting and ensure training and CPD 
requirements are fulfilled. At the same time it will build their confidence and experience 
as independent prescribers. This system will also provide maximum flexibility for an 
employer so that an agreed formulary of medicines, appropriate to individual NMPs and 
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their services, are agreed in a systematic and considered way. The length of the initial, 
transition period should be defined at a local level, but as a guide it is suggested that six 
months is appropriate for a newly qualified NMP and three months for an NMP newly 
recruited into the service. 
 
NMP in practice 
Rob has worked for four years as a specialist substance misuse NMP in the Liaison 
Psychiatry Department, Addenbrooke’s Hospital, Cambridge. He aims to see every 
patient who comes into the hospital with a substance misuse problem. While patients 
are in the acute hospital, Rob and his colleagues provide specialist treatment for their 
drug or alcohol dependence problems. 
 
Rob is able to provide immediate substitute prescriptions for opiate dependence and 
can prescribe benzodiazepines to prevent alcohol withdrawal. Typically, he sees people 
who have injecting injuries, complications from alcohol withdrawal or alcoholic liver 
disease. 
 
For patients admitted with alcohol dependence, Rob can start alcohol detoxification 
regimes for those with emergency gastritis, suspected Wernicke’s encephalopathy and 
injuries from falls or fights. When their primary presentation is resolved and the patient 
is ready for discharge, Rob liaises with the community alcohol nurses who immediately 
continue the detoxification medication. He also supervises the rest of the detoxification. 
 
Since the change in the law in 2012, Rob can independently prescribe opioid 
substitution medicines. Previously, he had to arrange for  a non-specialist physician to 
see the patient and prescribe for them or ask the addictions consultant psychiatrist to 
see the patient first to draw up a clinical management plan so that he could then act as 
a supplementary prescriber. Having Rob as an independent prescriber has enabled the 
hospital to provide much faster access to opioid substitution treatment. Many of the 
opiate-dependent patients are known to their local community drug teams and Rob 
ensures that their treatment is transferred to the community team or to their GP when 
they leave Addenbrooke’s Hospital. 
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3. Clinical governance to support NMPs 
3.1 Establishing NMP policies and standard operating procedures 
Once a provider service has taken the decision to embed NMP into its organisational 
structure, an NMP lead should be appointed to develop an appropriate policy and 
standard operating procedures (SOP). These will enable the service to incorporate NMP 
into its existing and future clinical governance arrangements. It is recommended that 
lead clinicians are included at every stage of planning and development of the NMP 
policy and SOP. 
 
The NMP policy and SOP will be tailored to a service’s specific needs. However, as a 
minimum an effective NMP policy will cover the following areas: 
 the benefits of NMP and the rationale for introducing NMP into the service. 
 the roles and responsibilities of the NMP (this should be understood by all team 
members) and the level of complexity of patients the NMP will prescribe for 
 who will manage and clinically supervise the NMP, and the formal mechanism for 
supervision (including frequency) 
 arrangements for monitoring the NMP’s prescribing practice  
 provisions to support the NMP’s CPD needs. This should include peer 
supervision/support. 
 provision for monitoring the NMP’s ongoing competence to prescribe within 
his/her practice area 
 the relevant local and national policies/procedures/guidance the NMP must work 
within  
 the requirement for appropriate professional indemnity arrangements 
 the initial period of support for newly qualified or newly appointed NMPs 
 
Note that the lead clinician, service manager and NMP are jointly responsible for 
guaranteeing that prescribing clinics are effectively organised and that the NMP 
prescribes in a way that fully complies with high standards of prescribing practice, the 
legal, professional and ethical requirements, and local policies. 
 
The NMP policy should also reflect that it is good practice to separate the process of 
prescribing and dispensing/administration whenever possible. Where NMPs are 
prescribing and dispensing (eg, pharmacist NMP) or prescribing and administering (eg, 
nurse NMP) for individual patients, a suitably competent second person should check 
the accuracy of the dispensed or administered medicine. 
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3.2 Role of the NMP lead 
Organisations using NMP were advised in 2006 guidance4 that they should have a lead 
director who is responsible for implementing their strategic plan for NMP. Since then, 
the NMP lead role has been widely adopted and the lead has been described as playing 
a significant part in making effective use of NMPs. However, two studies20 21 have found 
that leads lack dedicated time for their role and there is no standardised list of 
responsibilities or recruitment procedure for them. The NMP lead is well placed to help 
reduce the waste of resources caused when professionals take NMP training but then 
fail to prescribe in practice after qualification. 
 
Functions of the NMP lead 
Strategic 
influence 
Operational 
management 
Clinical 
governance 
 promote NMP in their 
organisation 
 provide information to 
managers liaise with 
HEIs 
 select candidates for 
NMP training 
 distribute resources, 
eg, the British National 
Formulary 
 support trainee and 
practising NMPs 
 arrange internal CPD 
events 
 keep a database of 
prescribers 
 monitor NMP activity 
through audit 
 update the organisation 
NMP policy 
 disseminate medicines 
alerts 
 collate specimen 
signatures 
 report incidents 
 ensure NMPs receive 
supervision and 
appraisal 
 
Mental health trusts have been slower than acute and primary care to take up NMP.22 
Specialist nurses and pharmacists in addictions are likely to be the exception to this with 
rapid expansion in numbers of NMPs working in substance misuse over the past five 
years.10 The NMP lead needs to make sure that the governance arrangements are 
suitably tailored to the high-volume prescribing practice that is typical of substance 
misuse community work. Establishing clear prerequisite preparatory training and 
protocols for prescribing practice before candidates undertake training will reduce drop 
out from training programmes and ensure NMPs actually prescribe once qualified. 
 
3.3 Assuring competence 
Pharmacists and nurses working as independent and supplementary prescribers in the 
substance misuse field need to work within a multidisciplinary team to ensure they are 
not working in isolation. They also need access to adequate and appropriate 
supervision. It is important that all members of the team understand that the NMP 
 18 
cannot prescribe outside of their area of competence and confidence. This area should 
be clearly defined, although it will likely grow with experience. 
 
Continuing professional development 
Prescribing is part of professional practice, so prescribers are accountable for remaining 
up to date and competent. Continuing professional development (CPD) appraisal for 
prescribers should be undertaken annually as part of performance review, preferably 
using a recognised tool – eg, the NPC generic competency prescribing framework.18 
Although prescribers are responsible for their own CPD, employers should support them 
in meeting these needs. 
 
CPD should suit the individual learning style of practitioners, and meet their learning 
needs. CPD can take a variety of forms, including peer support (eg, prescribing forums), 
journals, individual study, work-based learning (including clinical supervision and 
reflection on prescribing practice), and formal CPD study days. Where possible, CPD 
should be undertaken within a multi-disciplinary context. 
 
Supervision 
Clinical supervision should be provided by a specialist in substance misuse who is 
easily accessible to the NMP. This can be either a doctor or an experienced NMP. It is 
suggested that the NMP and clinical supervisor meet formally once a month to discuss 
prescribing practice, away from distractions and interruptions. These meetings will need 
to be more frequent initially (eg, weekly) such as when the NMP first joins the team. The 
clinical supervisor should also be accessible to the NMP on an ad hoc basis to discuss 
any immediate clinical issues that arise. 
 
Many services also provide management supervision for the NMP by a line manager 
who may not be a prescriber. Generally, management supervision is provided less 
frequently than clinical supervision (eg, every three months) although this is service-
specific. Where there is separate management supervision, the NMP’s clinical 
supervisor should be involved in developing the NMP’s learning and development 
objectives and have input in the NMP’s annual appraisal. 
 
Appraisal 
The NPC produced a single competency assessment framework18 for all prescribers 
that can be used as a tool to assess the competence of newly qualified or appointed 
NMPs, and as part of the annual appraisal process. The NMP, service’s NMP lead and 
clinical supervisor will together want to assess whether competence can be 
demonstrated against the framework within the NMP’s field of practice. The outcome of 
this assessment is best documented, and any development objectives identified added 
to the NMP’s development plan. 
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Peer support networks 
NMPs in the same or adjoining areas may find it useful to meet regularly and share best 
practice and case studies, or to observe and provide feedback on prescribing practice. 
A number of national and local networks support NMPs in the field of substance misuse. 
 
The National Substance Misuse Non-Medical Prescribing Forum (NSMNMPF) is for 
nurse and pharmacist prescribers in substance misuse. This forum holds free meetings 
three times a year across the country. For details see www.nmpsm.org 
 
SMMGP (Substance Misuse Management in General Practice) runs an online forum 
freely accessible to NMPs. www.smmgp.org.uk 
 
Regional peer support groups for non-medical prescribers in substance misuse include: 
 
 South West – NMPs across Devon and three treatment agencies meet monthly. 
This has been an effective environment for sharing prescribing dilemmas, 
sharing good practice and developing specific local prescribing guidelines and 
disseminating and addressing concerns relating to process and practice. 
 Birmingham – NMPs working with addiction meet monthly to discuss current 
issues. One of the NMPs will bring a case study for discussion, and another will 
bring a paper for discussion (a "journal club"). As such, the meetings have quite 
a strong learning and development focus, as well as being supportive to the 
group. 
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NMP in practice 
Reuben qualified as an NMP in an inner-city community drug and alcohol team and has 
a caseload of around 30 patients. The prescribing team has written protocols stating 
which drugs Reuben can prescribe as an NMP, and has agreed guidance on doses and 
dose adjustments. 
 
Reuben prescribes methadone and buprenorphine, and uses a patient group direction 
to issue take-home naloxone. For part of the week he provides a dedicated dose 
titration and stabilisation clinic where he sees patients who are starting a new treatment 
episode within the recovery orientated treatment system. He reviews their doses twice a 
week, or as required, and so stabilises them on prescribed opiates as quickly and safely 
as possible. During this intensive treatment period Reuben provides overdose training 
and take-home naloxone, manages blood-borne virus screening and vaccination, and 
screens all patients for health and nutrition. 
 
As part of his role he audits his prescribing decisions and carries out patient satisfaction 
surveys at the end of treatment. Patients report high levels of satisfaction, outcomes are 
good with high levels of engagement and successful onward referral to primary care or 
other key-workers, and the number of patients leaving treatment prematurely are low. At 
other times Reuben is a keyworker for his own caseload of patients and prescribes for 
them while they are under his care. 
 
An advantage for the service in having Reuben working as an NMP is that doctors are 
able to concentrate their efforts more efficiently on the most complex patients. Reuben 
benefits by being able to act more autonomously and feels that his relationships with 
patients are strengthened, and that patients are being reviewed by someone who has 
known them over an extended period. 
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4. Appendices 
Medicines legislation 
The Human Medicines Regulations 2012 (SI 2012/1916) came into force on 14 August 
2012. 
 
The regulations are the result of the MHRA’s consolidation and review of UK medicines 
legislation. They replace nearly all UK medicines legislation – most of the Medicines Act 
1968 and over 200 statutory instruments 
www.legislation.gov.uk/uksi/2012/1916/contents/made 
 
The regulations set out a comprehensive regime for the authorisation of medicinal 
products for human use; for the manufacture, import, distribution, sale and supply of 
those products; for their labeling and advertising; and for pharmacovigilance. 
 
Controlled drugs governance legislation and governance arrangements 
The prescription, administration and supply of medicines to substance misusers will, 
almost invariably, mean working with controlled drugs. Handling of CDs requires 
additional responsibilities. 
 
All healthcare professionals have an individual responsibility to ensure controlled drugs 
are managed safely. As part of this, it is essential that they are familiar with the 
legislation regarding possession, supply and safe storage of these drugs (Misuse of 
Drugs Act and supporting regulations) and those that relate more specifically to 
governance arrangements (The Controlled Drugs (Supervision of Management and 
Use) Regulations 2013). In particular, it is important for non-medical prescribers to be 
aware that all aspects of a controlled drug’s journey within a healthcare setting 
(including the safe storage of prescriptions) should be set out in a standard operating 
procedure (SOP) and know to whom they should report controlled drug incidents and 
concerns, no matter how small the incident might appear to be. This will include an 
awareness of the role of controlled drugs accountable officers (CDAOs), occurrence 
reporting, and controlled drugs local intelligence networks (CD LINs). 
 
Non-medical prescribers working within the addictions field are likely to be required to 
prescribe controlled drugs as part of their practice but must only do so within their 
sphere of confidence and competence. This should include the necessary knowledge 
and assessment skills to identify potential risks or complications of prescribing in 
addiction when patients have complex co-morbid conditions. Since April 2012, 
pharmacist and nurse independent prescribers have been allowed to prescribe any 
controlled drug for any medical condition within their competence, with the exception of 
diamorphine, cocaine and dipipanone for the treatment of addiction. 
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Controlled drugs legislation 
The management of controlled drugs is governed by two key sets of legislation, the 
Misuse of Drugs Act 1971 and supporting regulations (Home Office legislation) and The 
Controlled Drugs (Supervision of Management and Use) Regulations 2013 (Department 
of Health legislation). The main purpose of the Misuse of Drugs Act is to prevent the 
misuse of controlled drugs by imposing restrictions on their possession, supply, 
manufacture, import and export. The Department of Health regulations set out 
strengthened governance arrangements for controlled drugs used as medicines. 
 
Misuse of Drugs Act 1971 and Misuse of Drugs Regulations 2001 
Drugs controlled under the Misuse of Drugs Act 1971 are those that have the potential 
to be misused and they are classified according to their assessed harmfulness:  
www.legislation.gov.uk/ukpga/1971/38/contents 
 
Many controlled drugs are also essential to modern clinical care and their legitimate, 
clinical use is governed by the Misuse of Drugs Regulations 2001, which categorises 
them into five schedules based on their therapeutic usefulness and potential harms 
when misused:  
www.legislation.gov.uk/uksi/2001/3998/contents/made 
 
Misuse of Drugs Regulations 2001 amendment for nurse and pharmacist independent 
prescribers 
The Misuse of Drugs Regulations 2001 were amended in 2012 to allow nurse and 
pharmacist independent prescribers to prescribe any controlled drug listed in schedules 
2 to 5 for any medical condition within their competence, with the exception of 
diamorphine, cocaine and dipipanone for the treatment of addiction. The changes came 
into effect on 23 April 2012. 
 
The Controlled Drugs (Supervision of Management and Use) Regulations 2013 
The Shipman Inquiry was an independent public inquiry set up in 2001 to examine the 
issues arising from the case of Harold Shipman. The inquiry’s fourth report focused on 
the methods Shipman used to divert large quantities of controlled drugs for his own 
purposes, and considered how he was able to do it for so long without being detected. It 
concluded that there were serious shortcomings in the systems for regulating the 
governance of controlled drugs. In response, the Controlled Drugs (Supervision of 
Management and Use) Regulations 2006 were introduced and came into force in 
England on 1 January 2007. They have now been superseded by the new regulations, 
the Controlled Drugs (Supervision of Management and Use) Regulations 2013, which 
came into force on 1 April 2013 to reflect the changes in the NHS: 
www.legislation.gov.uk/uksi/2013/373/contents/made 
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The Department of Health has also published information about the regulations to 
support the changes made in legislation:  
www.gov.uk/government/uploads/system/uploads/attachment_data/file/214915/15-02-
2013-controlled-drugs-regulation-information.pdf 
 
The regulations require healthcare organisations such as NHS trusts and independent 
hospitals to appoint a controlled drugs accountable officer (CDAO) who has 
responsibility for all aspects of controlled drugs management within the organisation. 
Other organisations, such as substance misuse services, may not be required to 
appoint a CDAO but may want to consider appointing a lead to ensure controlled drug 
governance arrangements are in place within their organisation. They must still comply 
with the Misuse of Drugs Regulations and must have arrangements to ensure the safe 
and secure management of controlled drugs and the reporting of controlled drug 
concerns. Each area team of NHS England is also required to appoint a lead CDAO and 
to designate the controlled drugs local intelligence network(s) (LIN) for their area for the 
purpose of sharing controlled drug concerns. Each team determines the membership of 
its LIN and the meeting frequency. 
 
Details of all CDAOs in England are held in the controlled drugs accountable officer 
register, which is published on the CQC website: 
www.cqc.org.uk/content/controlled-drugs-accountable-officers 
 
Clinical guidance 
Drug misuse and dependence: UK guidelines on clinical management (commonly 
referred to as the Orange Book) provides guidance for all clinicians, especially those 
providing pharmacological interventions for drug misusers. NICE guidelines on drug and 
alcohol misuse and NICE technology appraisals relevant to non-medical prescribing in 
substance misuse management are listed below. 
 
 Alcohol-use disorders: Diagnosis and clinical management of alcohol-related 
physical complications (NICE clinical guideline 100, 2010) 
www.nice.org.uk/guidance/CG100 
 Alcohol-use disorders: Diagnosis, assessment and management of harmful 
drinking and alcohol dependence (NICE clinical guideline 115, 2011) 
www.nice.org.uk/guidance/CG115 
 Drug misuse: Psychosocial interventions (NICE clinical guideline 51, 2007) 
www.nice.org.uk/guidance/CG51 
 Drug misuse: Opioid detoxification (NICE clinical guideline 52, 2007) 
www.nice.org.uk/guidance/CG52 
 Methadone and buprenorphine for the management of opioid dependence (NICE 
technology appraisal 114, 2007) www.nice.org.uk/guidance/TA114 
 Naltrexone for the management of opioid dependence (NICE technology 
appraisal 115, 2007)  www.nice.org.uk/guidance/TA115  
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How this guidance came about  
Public Health England recognised the need for updated NMP guidance and asked the 
National Substance Misuse Non-Medical Prescribing Forum (NSMNMPF) to establish 
an expert group with the necessary representation to prepare guidance, based on the 
2007 NTA publication, that defines clear parameters within which non-medical 
prescribing can be delivered safely and effectively. Members of the expert group met 
between July 2013 and February 2014. 
Expert group members  
Mr Mike Flanagan (Chair), chair, NSMNMPF; consultant nurse, Surrey & Borders 
Partnership NHS Foundation Trust 
Dr Owen Bowden-Jones, addictions faculty chair, Royal College of Psychiatrists 
Dr Steve Brinksman, clinical lead, Substance Misuse Management in General Practice  
Mr Brian Brown, national pharmacy manager, Care Quality Commission 
Dr Carmel Clancy, chair, Association of Nurses in Substance Abuse; head of department, 
Middlesex University 
Professor Molly Courtenay, professor of clinical practice (prescribing and medicines 
management), University of Surrey 
Ms Sarah Dennison, national controlled drugs manager, Care Quality Commission 
Professor Matt Griffiths, visiting professor of prescribing and medicines management, 
Birmingham City University 
Mr Kevin Gwilt, standards development officer, Nursing and Midwifery Council 
Dr Linda Harris, medical director, substance misuse and associated health, Royal College 
of General Practitioners 
Mr Jamie Holmes, NMP clinical team lead, Shrublands House, Torquay  
Ms Joanne Martin, QA manager, General Pharmaceutical Council 
Ms Rosie Mundt-Leach, head of nursing, addictions clinical academic group, South 
London and Maudsley NHS Foundation Trust 
Ms Dawn Price, expert representative, Royal Pharmaceutical Society; chief pharmacist, 
Addaction 
Mr Kevin Ratcliffe, consultant pharmacist, Birmingham & Solihull Mental Health NHS 
Foundation Trust 
Policy observers 
Ms Rebecca Blessing, section head, non-medical prescribing and general prescribing 
issues, Department of Health 
Dr Mark Prunty, senior medical officer for substance misuse policy, Department of Health 
Ms Gul Root, principle pharmaceutical officer, Department of Health 
Additional advisers 
Dr Nat Wright, associate medical director specialist services and vulnerable groups, 
Leeds Community Healthcare 
Dr Gordon Morse, medical director, Turning Point; Royal College of General Practitioners 
Secretariat 
Mr Robert Wolstenholme, Public Health England 
Mr Steve Taylor, Public Health England 
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